429 related articles for article (PubMed ID: 30803159)
1. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections.
Hengzhuang W; Green K; Pressler T; Skov M; Katzenstein TL; Wu X; Høiby N
Pediatr Pulmonol; 2019 May; 54(5):575-580. PubMed ID: 30803159
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions.
Pompilio A; Crocetta V; Pomponio S; Fiscarelli E; Di Bonaventura G
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):318-25. PubMed ID: 26004353
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
Hengzhuang W; Wu H; Ciofu O; Song Z; Høiby N
Antimicrob Agents Chemother; 2012 May; 56(5):2683-90. PubMed ID: 22354300
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
5. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients.
Sans-Serramitjana E; Fusté E; Martínez-Garriga B; Merlos A; Pastor M; Pedraz JL; Esquisabel A; Bachiller D; Vinuesa T; Viñas M
J Cyst Fibros; 2016 Sep; 15(5):611-8. PubMed ID: 26708265
[TBL] [Abstract][Full Text] [Related]
6. Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates.
Díez-Aguilar M; Ekkelenkamp M; Morosini MI; Huertas N; Del Campo R; Zamora J; Fluit AC; Tunney MM; Obrecht D; Bernardini F; Cantón R
J Antimicrob Chemother; 2021 Sep; 76(10):2578-2585. PubMed ID: 34283223
[TBL] [Abstract][Full Text] [Related]
7. A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.
Pritchard MF; Powell LC; Jack AA; Powell K; Beck K; Florance H; Forton J; Rye PD; Dessen A; Hill KE; Thomas DW
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630204
[TBL] [Abstract][Full Text] [Related]
8. Activity of
Valzano F; Boncompagni SR; Micieli M; Di Maggio T; Di Pilato V; Colombini L; Santoro F; Pozzi G; Rossolini GM; Pallecchi L
Microbiol Spectr; 2022 Aug; 10(4):e0100622. PubMed ID: 35735984
[TBL] [Abstract][Full Text] [Related]
9. Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions.
Kolpen M; Appeldorff CF; Brandt S; Mousavi N; Kragh KN; Aydogan S; Uppal HA; Bjarnsholt T; Ciofu O; Høiby N; Jensen PØ
Pathog Dis; 2016 Feb; 74(1):ftv086. PubMed ID: 26458402
[TBL] [Abstract][Full Text] [Related]
10. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Conole D; Keating GM
Drugs; 2014 Mar; 74(3):377-87. PubMed ID: 24510624
[TBL] [Abstract][Full Text] [Related]
11. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
Hodson ME; Gallagher CG; Govan JR
Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
[TBL] [Abstract][Full Text] [Related]
12. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
Tappenden P; Harnan S; Uttley L; Mildred M; Walshaw M; Taylor C; Brownlee K
Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264
[TBL] [Abstract][Full Text] [Related]
13. Determination of the spatiotemporal dependence of
Sans-Serramitjana E; Jorba M; Pedraz JL; Vinuesa T; Viñas M
Int J Nanomedicine; 2017; 12():4409-4413. PubMed ID: 28652741
[TBL] [Abstract][Full Text] [Related]
14. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
Howlin RP; Cathie K; Hall-Stoodley L; Cornelius V; Duignan C; Allan RN; Fernandez BO; Barraud N; Bruce KD; Jefferies J; Kelso M; Kjelleberg S; Rice SA; Rogers GB; Pink S; Smith C; Sukhtankar PS; Salib R; Legg J; Carroll M; Daniels T; Feelisch M; Stoodley P; Clarke SC; Connett G; Faust SN; Webb JS
Mol Ther; 2017 Sep; 25(9):2104-2116. PubMed ID: 28750737
[TBL] [Abstract][Full Text] [Related]
16. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm.
Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O
Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260
[TBL] [Abstract][Full Text] [Related]
18. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
[TBL] [Abstract][Full Text] [Related]
19. OligoG CF-5/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model.
Hengzhuang W; Song Z; Ciofu O; Onsøyen E; Rye PD; Høiby N
Antimicrob Agents Chemother; 2016 May; 60(5):2620-6. PubMed ID: 26833153
[TBL] [Abstract][Full Text] [Related]
20. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa.
Lu Q; Girardi C; Zhang M; Bouhemad B; Louchahi K; Petitjean O; Wallet F; Becquemin MH; Le Naour G; Marquette CH; Rouby JJ
Intensive Care Med; 2010 Jul; 36(7):1147-55. PubMed ID: 20397007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
